Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ADXN 
Addex Therapeutics Ltd (ADXN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: ADXN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.5% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.44M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 1 | Beta 1.77 | 52 Weeks Range 6.51 - 12.05 | Updated Date 09/13/2025 |
52 Weeks Range 6.51 - 12.05 | Updated Date 09/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3521.74% | Operating Margin (TTM) -853.23% |
Management Effectiveness
Return on Assets (TTM) -25.09% | Return on Equity (TTM) -163.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7394390 | Price to Sales(TTM) 46.47 |
Enterprise Value 7394390 | Price to Sales(TTM) 46.47 | ||
Enterprise Value to Revenue 34.62 | Enterprise Value to EBITDA -0.76 | Shares Outstanding 1069140 | Shares Floating 26107116 |
Shares Outstanding 1069140 | Shares Floating 26107116 | ||
Percent Insiders - | Percent Institutions 0.03 |
Upturn AI SWOT
Addex Therapeutics Ltd
Company Overview
History and Background
Addex Therapeutics Ltd is a pharmaceutical company focusing on developing novel allosteric modulators for neurological diseases. Founded in 2002, it has evolved through preclinical and clinical development stages, aiming to address unmet needs in various therapeutic areas.
Core Business Areas
- Allosteric Modulator Development: Focuses on developing small molecule allosteric modulators targeting G protein-coupled receptors (GPCRs) and other receptors to treat neurological disorders.
Leadership and Structure
Addex Therapeutics Ltd has a management team led by a CEO and a board of directors overseeing strategic direction and operations.
Top Products and Market Share
Key Offerings
- Dipraglurant (ADX48621): Dipraglurant is being developed for the treatment of dystonia and other neurological disorders. Clinical trials are ongoing, and there is no current market share or revenue as the product is not yet approved. Competitors depend on specific indication and includes botulinum toxin and deep brain stimulation for dystonia.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with companies vying to develop and market innovative therapies for various diseases. Specifically, the area of neurological disorders is characterized by significant unmet needs and increasing research activity.
Positioning
Addex Therapeutics Ltd is positioned as a drug discovery company focused on allosteric modulation. Its competitive advantage lies in its proprietary technology and expertise in developing novel small molecules.
Total Addressable Market (TAM)
The TAM for neurological disorder treatments is substantial, estimated to be billions of dollars globally. Addex Therapeutics Ltd aims to capture a share of this market with its innovative drug candidates. No estimate can be provided.
Upturn SWOT Analysis
Strengths
- Proprietary Allosteric Modulator Platform
- Experienced Management Team
- Focus on Unmet Medical Needs
- Strong Intellectual Property Portfolio
Weaknesses
- Limited Financial Resources
- Dependence on Clinical Trial Success
- Lack of Commercialized Products
- High R&D Expenses
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Expansion of Pipeline into New Therapeutic Areas
- Positive Clinical Trial Results
- Regulatory Approvals
Threats
- Clinical Trial Failures
- Competition from Established Pharmaceutical Companies
- Changes in Regulatory Landscape
- Economic Downturn
Competitors and Market Share
Key Competitors
- TEVA
- BIIB
- ABBV
Competitive Landscape
Addex Therapeutics Ltd faces intense competition from larger pharmaceutical companies with greater resources and established market presence. Its competitive advantage lies in its unique allosteric modulator platform and focus on specific neurological indications.
Growth Trajectory and Initiatives
Historical Growth: Addex Therapeutics Ltd's growth has been primarily driven by preclinical and clinical development milestones.
Future Projections: Future growth is contingent upon successful clinical trial outcomes and potential partnerships.
Recent Initiatives: Focus on advancing Dipraglurant through clinical trials and exploring new therapeutic applications for its technology.
Summary
Addex Therapeutics Ltd is a clinical-stage pharmaceutical company with a focus on allosteric modulators. The company is currently in the early stages of development, and thus does not yet have any revenue or significant market share. The lack of revenue and reliance on clinical trials adds risk, but the unique technology offers potential. Addex needs to advance its pipeline and secure partnerships to achieve long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- ClinicalTrials.gov
- Public Filings
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and based on available data. The AI-based fundamental rating is generated based on the information available and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Addex Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-01-29 | Co-Founder, CEO & Director Mr. Timothy Mark Dyer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | |
Full time employees 2 | |||
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment pain, anxiety, addiction, cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.